When an unruptured thoracic aortic aneurysm presents in a patient with vascular Ehlers-Danlos syndrome, the underlying connective tissue fragility defines the clinical context and shapes every management decision. This is a rare but high-stakes scenario demanding a tailored, evidence-informed approach.

Clinical Scenario

Vascular Ehlers-Danlos syndrome is a rare disorder — affecting approximately 1 in 50,000 to 100,000 individuals — caused by pathogenic variants in COL3A1. It carries a substantial risk of spontaneous aortic and arterial dissections, aneurysms, and rupture, often occurring at young ages. An unruptured thoracic aortic aneurysm in this population reflects that underlying arterial vulnerability.

Treatment Approach

Management in this setting is built around education, lifestyle modification, and minimising exposure to invasive procedures where possible. Medical therapy involves a specific beta-blocker with vasodilatory properties as a central pharmacological component. The complete protocol — including sequencing, alternatives, and the full clinical rationale — is available via the link below.

References

DOI: 10.1161/CIR.0000000000001106

Vascular Ehlers-Danlos syndrome, affecting 1 in 50 000 to 100 000 individuals, is attributable to pathogenic variants in COL3A1 and leads to spontaneous aortic and arterial dissections, aneurysms, and rupture at young ages.
Medical therapy of vascular Ehlers-Danlos syndrome includes education, lifestyle modification, and avoidance of invasive procedures when possible.
Studies of celiprolol, a beta blocker with vasodilatory properties, have suggested a benefit in patients with vascular Ehlers-Danlos syndrome, but data were considered to be insufficient for US Food and Drug Administration (FDA) approval.
In the absence of data showing efficacy in vascular Ehlers-Danlos syndrome, other beta blockers are often prescribed, with some physicians choosing alternative beta blockers with vasodilatory properties.

View source ↗

Treatment of Unruptured Thoracic Aortic Aneurysm in Vascular Ehlers-Danlos Syndrome

Clinical Scenario

Treatment Approach

References